Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DNA methylation analysis of human fibroblasts and induced neurons (iNs) from a cohort of Alzheimer patients and controls

ABSTRACT: We have obtained fibroblast cultures from old adult human donors, including Alzheimer patients. The fibroblasts were reprogrammed into directly induced neurons (iNs) to serve as an adult-like and age-equivalent model for aging and neurodegeneration. We also generated iPSCs and rejuvenated iPSC-derived induced neurons from a subset of the same cohort as controls. The cells were analyzed using several assays, including mRNA-Seq, ATAC-Seq and DNA methylation EPIC array analysis.

ORGANISM(S): Homo sapiens

SUBMITTER: Jerome Mertens

PROVIDER: E-MTAB-10344 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

RNA-Seq of human fibroblasts, induced neurons (iNs), iPSCs, and iPSC-derived neurons, and ATAC-Seq of fibroblasts and iNs from a cohort of Alzheimer patients and controls

Project description:We have obtained fibroblast cultures from old adult human donors, including Alzheimer patients. The fibroblasts were reprogrammed into directly induced neurons (iNs) to serve as an adult-like and age-equivalent model for aging and neurodegeneration. We also generated iPSCs and rejuvenated iPSC-derived induced neurons from a subset of the same cohort as controls. The cells were analyzed using several assays, including mRNA-Seq, ATAC-Seq and DNA methylation EPIC array analysis.

2021-04-29 | E-MTAB-10352 | biostudies-arrayexpress

Cross-tissue transcriptomic analysis of human secondary lymphoid organ residing ILC3 reveals a default quiescent state in the absence of inflammation

Project description:A cross tissue transcriptional comparison of human ILC3 isolated from non-inflamed lymph nodes (LN) and spleens, inflamed tonsils and the peripheral blood (PB). Using uniform gating and high-purity cell-sorting, ILC3 were sorted as Lineage(CD3,CD19,CD34,CD14,CD94)-CD45intCD127+CRTH2-CD117+. From LN, spleen, tonsils and PB, NKp44- ILC3 were isolated and, in addition, NKp44+ ILC3 were sorted from spleen and tonsils. RNA quality was measured on a RNA 6000 Pico Kit (Agilent Technologies) using a 2100 Bioanalyzer (Agilent Technologies). 100 pg high-quality RNA was isolated and cDNA was generated using the SMART-Seq (v3) Ultra Low Input RNA Kit (Clontech) with 15 cycles of amplification. Amplified and Covaris-fragmented cDNA was quality-checked on a High Sensitivity DNA chip (Agilent Technologies) and further processed according the TruSeq Nano DNA Library Preparation Kit (Illumina). Data was processed as follows: SMARTer adapters were trimmed with cutadapt and the resulting sequences were aligned to the human RefSeq transcriptome using 14 TopHat2 (Kim et al., 2013). Normalization and quantification was performed using Cufflinks (Trapnell et al., 2012). FPKM counts were determined per gene with HTSeq-count. Raw data has been deposited at the European Genome-Phenome Archive (www.ebi.ac.uk/ega) under accession EGAS00001002636.

2017-07-31 | E-MTAB-5909 | biostudies-arrayexpress

Identification of new therapies based on systems biology approach (DECISION 5)

Project description:GSA from 562 out of 1841 patients with severe decompensated cirrhosis from the DECISION project. The DECISION project aims to discover more personalized combinatorial therapies for patients with decompensation of cirrhosis. This will be achieved by using readily available clinical data, prospectively collected in a homogenous manner from large clinical studies, with the corresponding standardized biobank samples that will produce omics data once they are fully analyzed. The data generated and analyzed in DECISION will directly serve as a basis for accomplishing the objectives of the project, i.e.: 1. Improving our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from fully characterized patients with available biological samples. 2. Identifying novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. 3. Developing 2 tests: One predicting the outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test), and the other identifying patients who will respond to the novel combinatorial therapy (test for response).

2024-12-18 | E-MTAB-12555 | biostudies-arrayexpress

Identification of new therapies based on systems biology approach (DECISION 4)

Project description:GSA from 278 out of 1841 patients with severe decompensated cirrhosis from the DECISION project. The DECISION project aims to discover more personalized combinatorial therapies for patients with decompensation of cirrhosis. This will be achieved by using readily available clinical data, prospectively collected in a homogenous manner from large clinical studies, with the corresponding standardized biobank samples that will produce omics data once they are fully analyzed. The data generated and analyzed in DECISION will directly serve as a basis for accomplishing the objectives of the project, i.e.: 1. Improving our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from fully characterized patients with available biological samples. 2. Identifying novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. 3. Developing 2 tests: One predicting the outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test), and the other identifying patients who will respond to the novel combinatorial therapy (test for response).

2024-12-18 | E-MTAB-12554 | biostudies-arrayexpress

Identification of new therapies based on systems biology approach (DECISION 3)

Project description:GSA from 387 out of 1841 patients with severe decompensated cirrhosis from the DECISION project. The DECISION project aims to discover more personalized combinatorial therapies for patients with decompensation of cirrhosis. This will be achieved by using readily available clinical data, prospectively collected in a homogenous manner from large clinical studies, with the corresponding standardized biobank samples that will produce omics data once they are fully analyzed. The data generated and analyzed in DECISION will directly serve as a basis for accomplishing the objectives of the project, i.e.: 1. Improving our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from fully characterized patients with available biological samples. 2. Identifying novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. 3. Developing 2 tests: One predicting the outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test), and the other identifying patients who will respond to the novel combinatorial therapy (test for response).

2024-12-18 | E-MTAB-12553 | biostudies-arrayexpress

Caldendrin regulates spine apparatus localization through myosin V-dependent ER-stabilization in dendritic spines

Project description:Excitatory synapses of principal hippocampal neurons are frequently located on dendritic spines. The dynamic strengthening or weakening of individual inputs results in a great structural and molecular diversity of dendritic spines. Active spines with large Ca2+-transients are frequently invaded by a single protrusion from the endoplasmic reticulum (ER), which is dynamically transported into spines by the actin-based motor myosin V. An increase in synaptic strength often correlates with stable anchoring of the ER, followed by the formation of the spine apparatus organelle. Here we characterize the newly identified interaction of myosin V with the Ca2+-sensor caldendrin, a brain-specific homolog of the well-known myosin V interactor calmodulin. While calmodulin is an essential activator of myosin V motor function, we found that caldendrin acts as an inhibitor of processive myosin V movement. We propose that caldendrin transforms myosin into a stationary F actin tether, and show that in mouse and rat hippocampal neurons, caldendrin regulates spine apparatus localization to a subset of dendritic spines through a myosin V-dependent pathway.

2022-01-27 | PXD029427 | Pride

Transcriptome profiling (RNA-seq) of human acute leukemias and healthy donors

Project description:Total RNA-seq of blasts derived 100 adult T-ALL cases, 211 AML cases and 13 mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). In addition, CD34+ HSPCs derived from 9 healthy donors are used as a control. Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011054, EGAD00001007646, EGAD00001007581 (datasets).

2023-08-31 | E-MTAB-13121 | biostudies-arrayexpress

DNA methylation (MCIP-seq) of human acute leukemias and healthy donors

Project description:To measure methylation, we employed Methyl-CpG-immunoprecipitation (MCIP) a technique which relies on a fusion protein consisting of the methyl-binding domain (MBD) of MBD2 and the Fc portion of IgG1 to detect methylated regions, exploiting the natural preference of MBD for 5-methylcytosine (5-mC). MCIP-seq was performed using the EpiMark® Methylated DNA Enrichment Kit. MCIP-seq of 77 primary samples obtained from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). Moreover, MCIP-seq of CD34+ HSPCs from 3 healthy donors is included. Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011052 (dataset).

2023-08-31 | E-MTAB-13120 | biostudies-arrayexpress

Hi-C of human acute leukemias and healthy donors

Project description:Hi-C of 17 primary samples obtained from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). As healthy controls, Hi-C of CD34+ HSPCs from 3 healthy donors were used. Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011051 (dataset).

2023-08-31 | E-MTAB-13122 | biostudies-arrayexpress

CTCF ChIP-seq of human acute leukemias

Project description:CTCF ChIP-seq of 39 primary samples derived from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011059 (dataset).

2023-08-31 | E-MTAB-13117 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data